Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer.

Lung cancer (Amsterdam, Netherlands) - 1 Aug 2018

Chaft Jamie E, Dagogo-Jack Ibiayi, Santini Fernando C, Eng Juliana, Yeap Beow Y, Izar Benjamin, Chin Emily, Jones David R, Kris Mark G, Shaw Alice T, Gainor Justin F

Abstract excerpt

OBJECTIVES: Reports of the prognostic significance of ALK-rearrangement in resected non-small cell lung cancer (NSCLC) have been contradictory. We aimed to determine the prognosis of early-stage ALK-positive lung cancers relative to KRAS- and EGFR-mutant lung cancers. MATERIAL AND METHODS: We reviewed medical records of patients with resected NSCLC harboring an ALK rearrangement (n = 29) or a driver mutation in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Rearrangement

Share to Neoplasm Staging

Share to Pneumonectomy

Share to Proto-Oncogene Proteins p21(ras)

Share to Survival Analysis

Share to United States

Source

Open in PubMed Open full text

Identifiers

PMID: 30032847
DOI: 10.1016/j.lungcan.2018.05.020
PMCID: PMC6062851

Genes

ALK
EGFR
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer.PMID 30032847Read ↗

Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib.Semantic proximity Read ↗

Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma.Semantic proximity Read ↗

Activating mutations within the EGFR kinase domain: a molecular predictor of disease-free survival in resected pulmonary adenocarcinoma.Semantic proximity Read ↗

Features of anaplastic lymphoma kinase rearrangement in early-stage lung cancer: Analysis of a nationwide Japanese database.Semantic proximity Read ↗

Clinicopathological and computed tomography features of patients with early-stage non-small-cell lung cancer harboring ALK rearrangement.Semantic proximity Read ↗

Patterns of DNA mutations and ALK rearrangement in resected node negative lung adenocarcinoma.Semantic proximity Read ↗

Mutations of the EGFR, K-ras, EML4-ALK, and BRAF genes in resected pathological stage I lung adenocarcinoma.Semantic proximity Read ↗

Radiologic Characteristics of Surgically Resected Non-Small Cell Lung Cancer With ALK Rearrangement or EGFR Mutations.Semantic proximity Read ↗

Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma.Semantic proximity Read ↗

The impact of EGFR mutation status on outcomes in patients with resected stage I non-small cell lung cancers.Semantic proximity Read ↗

Resected stage I anaplastic lymphoma kinase-positive lung adenocarcinoma has a negative impact on recurrence-free survival.Semantic proximity Read ↗

Mutations of the EGFR and K-ras genes in resected stage I lung adenocarcinoma and their clinical significance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.